Skin Rejuvenation With Topical Extract and Other Nutraceuticals

Sponsor
Medical Life Care Planners, LLC (Other)
Overall Status
Recruiting
CT.gov ID
NCT05734703
Collaborator
(none)
25
1
1
3
8.3

Study Details

Study Description

Brief Summary

Hemp extract has been shown in several pre-clinical and clinical studies to have anti-aging effects on the skin through anti-oxidant and anti-inflammatory effects, in addition resveratrol, thyme and caffeine have been shown to have anti-aging effects related to fibrillar collagen production and extracellular matrix production in the dermis.

A combination of these four ingredients will be used in a vehicle of fermented medium chain triglyceride oil and skin shave biopsies will be taken before and after 90 days use of the topical to look for objective evidence of anti-aging effects in the dermis and epidermis.

Condition or Disease Intervention/Treatment Phase
  • Drug: Nutraceutical Topical
Early Phase 1

Detailed Description

The study is a case series of 25 adults over age 50 identified through social media outreach in the Tampa Bay area. Each subject will be given a topical serum and advised to apply it once daily to the specific two by two inch area of skin under study (forearm or back of the neck). The serum will be comprised of hemp-extract, resveratrol, caffeine, thyme oil and fermented medium chain triglyceride as a vehicle. The skin anti-aging serum is expected to contain hemp-extract 5%, caffeine 2%, Thyme essential oil 2% and resveratrol 0.5%. The subjects will use the test formulation for 90 days. The subjects will jhave shaved skin biopsies taken on either the forearm or back of the neck. The biopsies will be done on day zero and on day 90.

None of the subjects are currently using anti-aging therapies. No other anti-aging therapy will be used during the 90 days of the research.

The subjects will be advised to apply a thin layer of the serum once each night at bedtime. To the area of skin under study (forearm or back of the neck). The one-ounce bottle of serum is expected to last for the entire 90 days of the study. The subjects will be reminded each day via text messaging to use the product and each subject will be required to text back that the daily treatment has been applied.

The 'before and after' shaved biopsies will be independently evaluated by Dr. Michael Morgan, board certified Dermatopathologist at KorPath, Inc. He will perform hematoxylin and eosin (H&E) staining, for histological analysis for morphology of the dermis and epidermis and histochemical staining for collagen and matrix analysis.

The subjects will be independently clinically evaluated by Dr. Kathy Anderson, board certified Dermatologist. She will determine "before and after" skin wrinkling scores using standard recognized metrics.

Each subject will have a diary app added to their smart phones to document daily use and potential adverse effects.

The results will be statistically evaluated with a standard for comparison. Study results with a p-value less than 0.05 will be determined to be statistically significant and the result will be evaluated for efficiency compared to generally recognized therapies

. The study will be prepared in standard fashion and submitted to recognized peer-review medical journals.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
25 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
One group of 25 adults aged 50 or over.One group of 25 adults aged 50 or over.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Skin Rejuvenation Using Topical Hemp-based Extract and Other Nutraceuticals
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Standard Topical Daily Dose

Only one arm in the study. Subjects treated with the topical daily for 90 days. The comparison will be 'before' and 'after' treatment skin biopsy results.

Drug: Nutraceutical Topical
Once daily application of the topical nutraceutical to two by two inch area of skin for 90 days.

Outcome Measures

Primary Outcome Measures

  1. dermal-epidermal juncton flattening [90 days]

    Histologic appearance of dermal-epidermal flattening on 'before' and 'after' skin biopsies.

  2. elastic fiber attenuation [90 days]

    Histologic appearance of elastic fiber attenuation in the dermis on 'before' and 'after' skin biopsies.

  3. denisty of collagen fiber network [90 days]

    Histologic appearance of the density of the collagen fibers on 'before' and 'after' skin biopsies.

Secondary Outcome Measures

  1. Glogau System: Wrinkle Severity Ranking [90 days]

    Glogau System: Wrinkle Severity Ranking score from 1-4 on 'before' and 'after' dermatologist physical examination of treated area

  2. Modified Fitzpatrick Wrinkle Scale [90 days]

    Modified Fitzpatrick Wrinkle Scale from class 0-2.5 on 'before' and 'after' dermatologist physical examination of treated area

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age 50 or over

  • Glogau Wrinkle Severity Scale of either 3 or 4 on the area to be biopsied.

  • Not on current anti-aging therapies used as an ingredient in the study topical.

Exclusion Criteria:
  • Under age 50

  • Glogau Wrinkle Severity Scale of either 1 or 2 on the area to be biopsied.

  • Currently using anti-aging therapies used as an ingredient in the study topical.

  • Contraindication to performing skin shave biopsies in the area to be biopsied.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Laser Scalp and Hair Center Clearwater Florida United States 33762

Sponsors and Collaborators

  • Medical Life Care Planners, LLC

Investigators

  • Principal Investigator: Gregory L Smith, MD, Nex Therapeutics, LLC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gregory L Smith, MD, MPH, Principal Investigaor, Medical Life Care Planners, LLC
ClinicalTrials.gov Identifier:
NCT05734703
Other Study ID Numbers:
  • Skin Antiaging Effects
First Posted:
Feb 21, 2023
Last Update Posted:
Feb 21, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Gregory L Smith, MD, MPH, Principal Investigaor, Medical Life Care Planners, LLC

Study Results

No Results Posted as of Feb 21, 2023